Wenbin Jiang Ph.D.
Cytek Biosciences, CEO

Dr. Jiang is a prolific inventor and a co-founder of Cytek Biosciences. As the CEO and Chairman of the Board, Dr. Jiang has led the company through four rounds of financing for a total of $200M raised, grown the company to multi-continents and achieved an average growth rate exceeding 100% over the life of the company.

Prior to Cytek Biosciences, Dr. Jiang served as CTO at Cosemi Technologies Inc. and JDSU Transmission Module BU. He received a PhD in Electrical Engineering from the University of California, Santa Barbara, a MS in Optics and a BS in Physics from Fudan University in Shanghai, China.

Over his career, he has contributed to 100 US patents, published more than 50 peer reviewed journal and conference papers, and wrote 5 book chapters. He has been awarded the Motorola Master Innovator Award and JDSU Inventor of the Year.

Jack Ball
Solulink Inc., CEO

Jack Ball has served as a member of our board of directors since September 2018. Mr. Ball also serves as the President of Tyball Associates LLC and serves on the board of directors of Carterra, Inc., a biotechnology company, KromaTiD, Inc., a biotechnology company and NanoCellect Biomedical, Inc., a biotechnology company. From October 2010 to March 2021, Mr. Ball served on the board of directors of Swift Biosciences Inc., a biotechnology company. From September 2013 to December 2019, Mr. Ball served as Chief Executive Officer and a board member at Solulink Inc., a biotechnology company. From February 2006 to July 2011, Mr. Ball was Chief Commercial Officer at Accuri Cytometers, Inc., a medical instruments company, which was sold to Becton Dickinson & Co in March 2011. Prior to that, Mr. Ball was Chief Executive Officer at Amnis Corporation, a biotechnology company, Chief Commercial Officer at Molecular Probes, Inc., a biotechnology company, Senior Vice President and General Manager at Orchid Biosciences, a DNA testing services biotechnology company and President for North America at Amersham Biosciences Corp., a healthcare company. Mr. Ball holds a B.S. in Agriculture from the University of Georgia.

Ming Yan Ph.D.
Cytek Biosciences, CTO

Dr. Yan is a co-founder of Cytek Biosciences with over 25 years of R&D experience in leadership and innovation. As CTO of Cytek, Ming leads the development team (including hardware, software, reagents, and applications), and with the team, drives the advancement of the Cytek Platform.

Prior to Cytek, Ming worked in the biomedical instruments industry and integrated photonics at AT&T Bell laboratories, Livermore national laboratories, Neophotonics and BD Biosciences. Ming is one of the thought-leaders in flow cytometry instrumentation and standardization. He received his Ph.D in Electrical Engineering and MS in Physics from City University of New York, BS in Physics from Fudan University.

Dr. Yan has published over 40 research papers relating to laser spectroscopy and cell analysis in top peer-reviewed journals. He has over a dozen patents and patent pending applications for his innovations.

Feng Deng
Northern Light Venture Capital

Mr. Feng Deng founded Northern Light Venture Capital (NLVC) in 2005. He currently manages over US$ 4.5 billion. He has led and backed nearly 200 companies, focusing on 4 main sectors: TMT (technology, media and telecom), clean technology, healthcare and consumer.

Prior to NLVC, Feng was a co-founder of NetScreen Technologies, which went public on NASDAQ and was later acquired by Juniper Networks in 2004 for US$ 4.2 billion. He has extensive technical and managerial experiences in computer, communication and data networking industries.

Feng holds BS and MS degrees in electrical engineering from Tsinghua University, a MS degree in computer engineering from the University of Southern California, and a MBA degree from the Wharton School, University of Pennsylvania. He also holds numerous patents of invention in computer system architecture and IC design.

Gisele Dion
Takeda Pharmaceutical

Gisele Dion has served as a member of our board of directors since March 2021. Ms. Dion was the Senior Advisor to the Chief Financial Officer of Takeda Pharmaceutical Ltd., a pharmaceutical company. Prior, she served as the Senior Vice President, Chief Accounting Officer and Corporate Controller at Takeda Pharmaceutical Ltd. from January 2019 to March 2021.

Ms. Dion served as the Senior Vice President, Chief Accounting Officer and Corporate Controller at Shire Pharmaceuticals LLC, a biopharmaceutical company, from January 2016 to January 2019. From 2007 to January 2016, she served as Corporate Controller and Senior Director of Technical Accounting of Biogen Inc., a biotechnology company.

Ms. Dion received a B.S. in Accounting and Management Information Systems from Fairfield University.

Tess Cameron
RA Capital Management

Tess Cameron has served as a member of our board of directors since April 2021. Ms. Cameron is the Principal, Strategic Finance at RA Capital Management, LP. From January 2018 to June 2020, Ms. Cameron served as the Head of Finance of Foghorn Therapeutics, Inc., a pharmaceutical company. From January 2017 to January 2018, Ms. Cameron served as the Director, Financial and Business Planning at WAVE Life Sciences Ltd., a biotechnology company.

Prior to that Ms. Cameron was the Associate Director, Finance Business Planning and Senior Finance Manager at Biogen Inc., a biotechnology company and worked at McKinsey & Company, a management consulting company.

Ms. Cameron holds a B.A. in Economics and Peace Conflict Studies from Victoria University, University of Toronto and graduated from the Mini-MBA program at the Tuck School of Business, Dartmouth College.

Vera Imper Ph.D.
Independent Advisor

Vera Imper has served as a board member of our Board of Directors since December 2021. Dr. Imper served as Vice President and Head, Business Development of Roche Molecular Solutions from January 2018 to November 2021. Dr. Imper previously served as Vice President, Worldwide Business Development of Becton Dickinson Biosciences from May 2009 to October 2017.

Dr. Imper holds a Ph.D. in Bioinorganic Chemistry, an M.S. in Physical and Organic Chemistry, and a B.S. in Pharmacy and Biochemistry from University of Zagreb.

Communication with Directors

Stockholders and interested parties who wish to communicate with our board of directors, non-management members of our board of directors as a group, a committee of the board of directors or a specific member of our board of directors (including our chairperson or lead independent director, if any) may do so by letters addressed to the attention of our Corporate Secretary or by sending an email to the board of directors at board@cytekbio.com.

All communications are reviewed by the Corporate Secretary and provided to the members of the board of directors consistent with a screening policy providing that unsolicited items, sales materials, abusive, threatening or otherwise inappropriate materials and other routine items and items unrelated to the duties and responsibilities of the board of directors will not be provided to directors. Any communication that is not provided to directors is recorded in a log and made available to our board of directors.

The address for these communications is:

Cytek Biosciences, Inc.
c/o Corporate Secretary
47215 Lakeview Boulevard
Fremont, California 94538

Search Investor Relations